53 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
million primarily due to the reacquired mavacamten rights of $445 million in China and certain other Asian territories. On a GAAP and non-GAAP basis
8-K
EX-99.1
bldzgyqsa8sa7seuyt2u
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K/A
EX-99.1
fje4p fs7h8
5 Feb 20
Report of Independent Registered Public Accounting Firm
4:42pm
8-K
EX-99.1
f13vggu aycyrsx
8 Mar 19
Report of Independent Registered Public Accounting Firm
7:02am
425
EX-99.1
ba7mh9jf8ruhpjrw4o
8 Mar 19
Business combination disclosure
7:00am
425
u1rpb05ss6
19 Feb 19
Business combination disclosure
5:21pm
8-K
EX-99.1
01jsqu0i1d3
19 Dec 18
Bristol-Myers Squibb Announces Offer from
4:19pm